Axsome Soars After Depression Trial Success
$1bn+ Peak Revenues Forecast Once Approved
Axsome is set to file for approval in the second half of 2020.
You may also be interested in...
The firm reorganized to focus on hemoglobinopathies and cancers after Celgene ended a multi-drug partnership. Also, Flagship funds a gene therapy start-up and brings in a business development veteran, Ultragenyx raises $320m in a royalty deal and Paratek secures up to $285m from BARDA.
The EMA has received written interventions from third parties relating to its CHMP opinion that the controversial antidepressant should receive EU approval.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.